The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma (MPC) treated with FOLFIRINOX or gemcitabine (gem) in a randomized phase III study (ACCORD11/PRODIGE4).
Marie Robert
No relevant relationships to disclose
Marta Jarlier
No relevant relationships to disclose
Thierry Conroy
No relevant relationships to disclose
Sophie Gourgou
No relevant relationships to disclose
Françoise Desseigne
No relevant relationships to disclose
Marc Ychou
No relevant relationships to disclose
Olivier Bouche
No relevant relationships to disclose
Beata Juzyna
No relevant relationships to disclose
Jaafar Bennouna
No relevant relationships to disclose